Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 9/20 | 0.79 |
| ▸ | LMNA | P02545 | 9/20 | 0.79 |
| ▸ | MAPT | P10636 | 6/20 | 0.79 |
| ▸ | TSHR | P16473 | 5/20 | 0.79 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.79 |
| ▸ | PGR | P06401 | 4/20 | 0.79 |
| ▸ | AR | P10275 | 4/20 | 0.79 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.79 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.79 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.79 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.71 |
| ▸ | SHBG | P04278 | 4/20 | 0.71 |
| ▸ | SERPINA6 | P08185 | 4/20 | 0.71 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.71 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7996078 | 1.00 | CYP3A4 (0.79) | CYP3A4LMNAMAPTTSHRNR3C1 | |
| SCHEMBL547898 | 1.00 | CYP3A4 (0.79) | CYP3A4LMNAMAPTTSHRNR3C1 | |
| SCHEMBL4617563 | 1.00 | CYP3A4 (0.79) | CYP3A4LMNAMAPTTSHRNR3C1 | |
| SCHEMBL2082800 | 1.00 | CYP3A4 (0.79) | CYP3A4LMNAMAPTTSHRNR3C1 | |
| SCHEMBL18438757 | 1.00 | CYP3A4 (0.79) | CYP3A4LMNAMAPTTSHRNR3C1 | |
| SCHEMBL15369348 | 1.00 | CYP3A4 (0.79) | CYP3A4LMNAMAPTTSHRNR3C1 | |
| SCHEMBL2600420 | 1.00 | CYP3A4 (0.79) | CYP3A4LMNAMAPTTSHRNR3C1 | |
| Propionic Acid SCHEMBL26659955 | 0.94 | CYP3A4 (0.80) | CYP3A4LMNAMAPTTSHRNR3C1 | |
| SCHEMBL8814296 | 0.92 | CYP3A4 (0.80) | CYP3A4LMNAMAPTTSHRNR3C1 | |
| Butyric Acid SCHEMBL26659976 | 0.91 | CYP3A4 (0.73) | CYP3A4LMNAMAPTTSHRNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2660241-A2 | C-17-HETEROARYL STEROIDAL COMPOUNDS AS INHIBITORS OF CYP11B, CYP17, AND/OR CYP21 | BioMarin Pharmaceutical Inc. (US) | 2013-11-06 | — | — | EP | disclosed |
| US-20130252930-A1 | CYP11B, CYP17, AND/OR CYP21 INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (CA) | 2013-09-26 | — | — | US | disclosed |
| US-20130252930-A1 | CYP11B, CYP17, AND/OR CYP21 INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (CA) | 2013-09-26 | — | — | US | disclosed |
| US-8486374-B2 | Alcohol-free drug or cosmetics carrier mixture of water, hydrophobic solvent, surfactant and gelling agent; oil in water emulsions | FOAMIX LTD. (IL) | 2013-07-16 | — | — | US | disclosed |
| WO-2012083112-A2 | CYP11B, CYP17, AND/OR CYP21 INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (US) | 2012-06-21 | — | — | WO | disclosed |
| US-20080299220-A1 | HYDROPHILIC, NON-AQUEOUS PHARMACEUTICAL CARRIERS AND COMPOSITIONS AND USES | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2008-12-04 | — | — | US | disclosed |
| US-20080292560-A1 | SILICONE IN GLYCOL PHARMACEUTICAL AND COSMETIC COMPOSITIONS WITH ACCOMMODATING AGENT | FOAMIX PHARMACEUTICALS LTD. (IL) | 2008-11-27 | — | — | US | disclosed |
| US-20080206161-A1 | QUIESCENT FOAMABLE COMPOSITIONS, STEROIDS, KITS AND USES THEREOF | FOAMIX PHARMACEUTICALS LTD. (IL) | 2008-08-28 | — | — | US | disclosed |
| US-20080063607-A1 | Oleaginous pharmaceutical and cosmetic foam | FOAMIX LTD | 2008-03-13 | — | — | US | disclosed |
| EP-1890679-A2 | STEROID KIT AND FOAMABLE COMPOSITION AND USES THEREOF | Foamix Ltd. (IL) | 2008-02-27 | — | — | EP | disclosed |
| US-20070292461-A1 | Oleaginous pharmaceutical and cosmetic foam | FOAMIX LTD. (IL) | 2007-12-20 | — | — | US | disclosed |
| WO-2007012977-A2 | STEROID KIT AND FOAMABLE COMPOSITION AND USES THEREOF | FOAMIX LTD (US) | 2007-02-01 | — | — | WO | disclosed |
| US-20060018937-A1 | Steroid kit and foamable composition and uses thereof | FOAMIX LTD. | 2006-01-26 | — | — | US | disclosed |
| EP-0528876-B1 | 2-IODO-3-KETO-DELTA 4 -STEROIDS, PROCESS FOR PRODUCING THEM AND THEIR FURTHER PROCESSING | SCHERING AG (DE) | 1995-04-12 | — | — | EP | disclosed |
| US-5391778-A | 2-iodo-3-keto-Δ4 steroids, process for their production, as well as their further processing | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-02-21 | — | — | US | disclosed |
| EP-0528876-A1 | 2-IODO-3-KETO-DELTA?4 -STEROIDS, PROCESS FOR PRODUCING THEM AND THEIR FURTHER PROCESSING. | SCHERING AG (DE) | 1993-03-03 | — | — | EP | disclosed |
| WO-1991017175-A1 | 2-IODO-3-KETO-DELTA4-STEROIDS, PROCESS FOR PRODUCING THEM AND THEIR FURTHER PROCESSING | SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) | 1991-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080206161-A1 | QUIESCENT FOAMABLE COMPOSITIONS, STEROIDS, KITS AND USES THEREOF | NR5A1, CYP17A1, LIPA | CYP3A4 2975/4885LMNA 266/4885MAPT 4587/4885 |
| US-20080292560-A1 | SILICONE IN GLYCOL PHARMACEUTICAL AND COSMETIC COMPOSITIONS WITH ACCOMMODATING AGENT | SSTR2, SSTR3, LPXN | CYP3A4 3893/4885LMNA 1641/4885MAPT 1240/4885 |
| US-20070292461-A1 | Oleaginous pharmaceutical and cosmetic foam | LIPA, LIPC, PLIN3 | CYP3A4 3451/4885LMNA 2105/4885MAPT 2679/4885 |
| US-20080063607-A1 | Oleaginous pharmaceutical and cosmetic foam | LIPA, LIPC, PLIN3 | CYP3A4 3451/4885LMNA 2105/4885MAPT 2679/4885 |
| US-20130252930-A1 | CYP11B, CYP17, AND/OR CYP21 INHIBITORS | CYP4A11, HSD17B11, CYP21A2 | CYP3A4 44/4885LMNA 1844/4885MAPT 1918/4885 |
| US-20080299220-A1 | HYDROPHILIC, NON-AQUEOUS PHARMACEUTICAL CARRIERS AND COMPOSITIONS AND USES | LIPA, PHOSPHO1, MYO1G | CYP3A4 1512/4885LMNA 524/4885MAPT 1026/4885 |
| US-20060018937-A1 | Steroid kit and foamable composition and uses thereof | KIT, GK, HSD17B7 | CYP3A4 2806/4885LMNA 1235/4885MAPT 3575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.